Azitra to Present at Microbiome Times Partnering Forum

Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [2] - The lead product, ATR-12, is designed to treat Netherton syndrome, a rare chronic skin disease with no approved treatment options [2] - ATR-04, another product, is being developed for EGFR inhibitor associated rash, which affects approximately 150,000 people in the U.S. [2] Clinical Development - ATR-12 is currently being evaluated in a Phase 1b clinical trial in adult patients with Netherton syndrome [2] - Azitra has received Fast Track designation from the FDA for ATR-04 targeting EGFRi associated rash [2] - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technology [2] Upcoming Events - Chief Operating Officer Travis Whitfill will present at the Microbiome Times Partnering Forum in Brussels on March 19, 2025 [1] - The presentation will focus on early clinical experience with ATR-12 for treating skin diseases [1] - Azitra's management team will conduct one-on-one meetings with registered investors and potential partners during the conference [1]